Mga Batayang Estadistika
| CIK | 1789769 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Instil Bio, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update With the clearance of the U. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exac |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 28, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 27, 2025 |
Exhibit 99.1 Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, sub |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 22, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 22, 2025 |
Instil Bio Corporate Presentation May 2025 Nasdaq: TIL | www.instilbio.com EX-99.1 Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” "expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “will,” and “target |
|
| May 13, 2025 |
a101instil-proposedamend 318569673 v2 Exhibit 10.1 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) by and between Sandeep Laumas (“Executive”) and Instil Bio, Inc. (the “Company”) is effective as of May 12, 2025 (the “Effective Date”) and amends and restates in its entirety the Amended and Restated Execut |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 13, 2025 |
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exa |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 31, 2025 |
Up to $100,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-283205 PROSPECTUS SUPPLEMENT (To Prospectus dated November 21, 2024) Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the s |
|
| March 31, 2025 |
, by and between the Company and Jefferies LLC, dated March 28, 2025. Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 28, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Instil Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, p |
|
| March 4, 2025 |
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U. |
|
| March 4, 2025 |
exhibit107feetableinstil Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Instil Bio, Inc. |
|
| March 4, 2025 |
203576221 Exhibit 10.13 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL TERM LOAN AGREEMENT between COMPLEX THERAPEUTICS LLC, a Delaware limited liability company, as Borrower and MIDLAND NATIONAL LIFE INSURANCE COMPANY, an Iowa corporation, as L |
|
| March 4, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 INSTIL BIO, INC. LIST OF SUBSIDIARIES Name of Entity Jurisdiction of Organization 1. Instil Bio (UK) Limited United Kingdom 2. Cellular Therapeutics Limited United Kingdom 3. Complex Therapeutics Mezzanine LLC Delaware 4. Complex Therapeutics LLC Delaware 5. Axion Bio, Inc (formerly SynBioTx, Inc.) Delaware |
|
| March 4, 2025 |
March 4, 2025 Nasdaq: TIL │ www.instilbio.com AXN-2510 3rd -Most Advanced PD-L1xVEGF Bispecific Antibody in Clinical Development *Axion Bio, Inc. (fka SynBioTx, Inc.) is a wholly owned subsidiary of Instil Bio, Inc. Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate |
|
| March 4, 2025 |
ex-191instilbioxinsidert INSTIL BIO, INC. INSIDER TRADING AND WINDOW PERIOD POLICY AMENDED MARCH 3, 2025 I. INTRODUCTION This policy determines acceptable transactions in the securities of Instil Bio, Inc. (the “Company”) by our employees, directors and consultants, and the employees, directors and consultants of our subsidiaries. During the course of your employment, directorship or consultancy w |
|
| March 4, 2025 |
203576230 Exhibit 10.14 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL RECOURSE INDEMNITY AGREEMENT THIS RECOURSE INDEMNITY AGREEMENT (this “Indemnity”) is made as of December 20, 2024, by INSTIL BIO, INC., a Delaware corporation (“Indemnitor”), |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exact na |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 14, 2025 |
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals Dallas, Texas, Jan. |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 19, 2024 |
INSTIL BIO, INC. 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 (972) 499-3350 INSTIL BIO, INC. 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 (972) 499-3350 November 19, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Instil Bio, Inc. Registration Statement on Form S-3 Filed November13, 2024 File No. 333- 283205 Ladies and Gentlemen: In accordance with Rule 461 und |
|
| November 14, 2024 |
TIL / Instil Bio, Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428137d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Instil Bio, Inc. (Name of Issuer) Common Stock, $0.000001 par value per share (Title of Class of Securities) 45783C200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
TIL / Instil Bio, Inc. / Vivo Capital IX, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Instil Bio, Inc. (Name of Issuer) Common stock, par value $ 0.000001 per share (Title of Class of Securities) 45783C200 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 14, 2024 |
EX-99.1 2 ea022116104ex99-1instil.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint |
|
| November 13, 2024 |
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. |
|
| November 13, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INSTIL BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws |
|
| November 13, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INSTIL BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws |
|
| November 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Instil Bio, Inc. |
|
| November 13, 2024 |
As filed with the Securities and Exchange Commission on November 13, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2024 Registration No. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INSTIL BIO, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] a |
|
| November 13, 2024 |
Exhibit 4.3 INSTIL BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2. |
|
| October 25, 2024 |
TIL / Instil Bio, Inc. / Boxer Capital Management, LLC Passive Investment SC 13G/A 1 ff403186513ga1-instil.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 (Title of Class of Securities) 45783C200 (CUSIP Number) October 10, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| October 25, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-2 2 ff4031865ex2-instil.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Common Stock of Instil Bio, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity |
|
| October 22, 2024 |
EX-99.A 2 d890198dex99a.htm EX-99.A Exhibit A Joint Filing Agreement The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Instil Bio, Inc., dated as of October 22, 2024, is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the |
|
| October 22, 2024 |
TIL / Instil Bio, Inc. / Curative Ventures V LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 (Title of Class of Securities) 4578C101 (CUSIP NUMBER) Curative Ventures V LLC 3963 Maple Avenue Suite 390 Dallas, Texas 75219 (Name, Address and Telephone Number of Person Authorized to Rece |
|
| September 27, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 ff3902993ex991-instilbio.htm Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Common Stock of Instil Bio, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned |
|
| September 27, 2024 |
TIL / Instil Bio, Inc. / Boxer Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 45783C200 (CUSIP Number) September 18, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| September 27, 2024 |
TIL / Instil Bio, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 45783C200 (CUSIP Number) September 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| September 27, 2024 |
EX-99.1 2 d832157dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: September 27, |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 16, 2024 |
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer •Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC) •Global registrational strategy in first-line triple-negative breast cancer (TNBC) •Initiation of Phase 1b/2 |
|
| September 16, 2024 |
instilbiocorppres2024091 Instil Bio Corporate Presentation September 2024 Nasdaq: TIL │ www. |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 15, 2024 |
SYN-2510 Program Overview August 2024 Nasdaq: TIL │ www.instilbio.com Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” "expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” and “will” or similar expression |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 13, 2024 |
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update –In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4 antibody –Entered into a 15-year lease for our cell therapy manufacturing facility to AstraZeneca Pharmaceuticals LP DALLAS, TX, August 13, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| August 13, 2024 |
64302122.5 Execution Version FIRST AMENDMENT TO MEZZANINE LOAN AGREEMENT AND OMNIBUS AMENDMENT TO MEZZANINE LOAN DOCUMENTS THIS FIRST AMENDMENT TO MEZZANINE LOAN AGREEMENT AND OMNIBUS AMENDMENT TO MEZZANINE LOAN DOCUMENTS (this “Amendment”), dated as of July 10, 2024 (the “Amendment Date”), is made by and among OP USA DEBT HOLDINGS II LIMITED PARTNERSHIP, an Ontario limited partnership (as success |
|
| August 13, 2024 |
Confidential Execution Version LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into as of August 1, 2024 (the “Effective Date”) between IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. |
|
| August 13, 2024 |
64265970.6 Execution Version FIRST AMENDMENT TO LOAN AGREEMENT AND OMNIBUS AMENDMENT TO LOAN DOCUMENTS THIS FIRST AMENDMENT TO LOAN AGREEMENT AND OMNIBUS AMENDMENT TO LOAN DOCUMENTS (this “Amendment”), dated as of July 10, 2024 (the “Amendment Date”), is made by and among OP USA DEBT HOLDINGS II LIMITED PARTNERSHIP, an Ontario limited partnership (as successor-by-assignment to OPG Hermes Investmen |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 13, 2024 |
52757516.2 Exhibit 10.3 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LEASE BY AND BETWEEN COMPLEX THERAPEUTICS LLC, a Delaware limited liability company (“Landlord”) and ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership (“Tenant”) |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exac |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 10, 2024 |
297175162 v1 February 12, 2024 Sandeep Laumas, CFO/CBO Re: 2024 Retention Bonus Agreement Dear Steve: As we have shared with you, Instil Bio, Inc. |
|
| May 10, 2024 |
297175162 v1 February 12, 2024 Bronson Crouch, CEO Re: 2024 Retention Bonus Agreement Dear Bronson: As we have shared with you, Instil Bio, Inc. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exa |
|
| May 10, 2024 |
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update DALLAS, TX, May 10, 2024 (GLOBE NEWSWIRE) - Instil Bio, Inc. |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 2, 2024 |
TIL / Instil Bio, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G 1 til13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* Instil Bio Inc (Name of Issuer) Common Stock, $0.000001 par value per share (Title of Class of Securities) 45783C101 (CUSIP Number) Mar |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024 As filed with the Securities and Exchange Commission on March 21, 2024 Registration No. |
|
| March 21, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Instil Bio, Inc. |
|
| March 21, 2024 |
Amended and Restated Non-Employee Director Compensation Policy EXHIBIT 10.6 Instil Bio, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Instil Bio, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Co |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 21, 2024 |
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, TX, March 21, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exact na |
|
| March 21, 2024 |
Incentive Compensation Recoupment Policy EXHIBIT 97.1 INSTIL BIO, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Instil Bio, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) |
|
| March 21, 2024 |
CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSTIL BIO, INC. |
|
| February 14, 2024 |
Form of Retention Bonus Agreement. Exhibit 10.1 February 12, 2024 [Name and Title] Re: 2024 Retention Bonus Agreement Dear : As we have shared with you, Instil Bio, Inc. (the “Company”) is offering you the retention bonus described in this letter (this “2024 Retention Bonus Agreement” or this “Agreement”) as an incentive for your continued service to the Company over the next year. If you sign this 2024 Retention Bonus Agreement, y |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2024 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 16, 2024 |
Instil Bio Announces Strategic Update Instil Bio Announces Strategic Update DALLAS, TX, January 16, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 8, 2023 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of Instil Bio, Inc. |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 13, 2023 |
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update DRAFT - DO NOT DISTRIBUTE Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update DALLAS, TX, November 13, 2023 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc |
|
| November 13, 2023 |
DRAFT - DO NOT DISTRIBUTE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2023 |
Separation Agreement, by and between the Registrant and Sumita Ray, dated as of April 14, 2023. EXHIBIT 10.1 Instil Bio, Inc. April 14, 2023 Sumita Ray Via Hand-Delivery / E-Mail Re: Separation Agreement Dear Sumita: This letter sets forth the terms of the separation agreement (the “Agreement”) that Instil Bio, Inc. (the “Company”) is offering to aid in your employment transition. 1.Separation. Your last day of work with the Company and your employment termination date will be May 9, 2023 (t |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exac |
|
| August 14, 2023 |
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, TX, August 14, 2023 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 26, 2023 |
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITIL-306 anticipated in 2024 DALLAS, TX, June 26, 2023 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exa |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 11, 2023 |
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, TX, May 11, 2023 (GLOBE NEWSWIRE) - Instil Bio, Inc. |
|
| May 11, 2023 |
February 22, 2023 Michael Bronson Crouch, Chief Executive Officer Re: One-Year Retention Bonus Agreement for Executive Officers Dear Bronson: As you have been informed, Instil Bio, Inc. |
|
| May 11, 2023 |
Agreement, by and between the Registrant and February 22, 2023 Sandeep “Steve” Laumas, M.D., Chief Financial Officer Re: One-Year Retention Bonus Agreement for Executive Officers Dear Steve: As you have been informed, Instil Bio, Inc. (the “Company”) is offering you the retention bonus described in this letter (the “One-Year Bonus Agreement”) as an incentive for your continued service to the Company in the coming years. If you sign this One- |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 31, 2023 |
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 DALLAS, TX, March 31, 2023 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exact na |
|
| March 31, 2023 |
separationagreement-inst 277314868 v3 November 11, 2022 Zachary Roberts c/o counsel, Richard Davis (rdavis@richardwdavis. |
|
| March 31, 2023 |
DESCRIPTION OF COMMON STOCK The following description summarizes the most important terms of our common stock. |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 31, 2023 |
sumitarayemploymentagree 1. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) by and between Sumita Ray (“Employee”) and Instil Bio Inc. (the “Company”) is effective as of April 18, 2022 (the “Effective Date”). The Company desires to employ Employee as its Chief Legal, Compliance and Administrative Officer and Corporate Secretary (hereinafter “Chief Legal and Administrative Officer” |
|
| March 31, 2023 |
instilbio-tmooreseparati 278719272 v2 INSTIL BIO, INC. December 8, 2022 Timothy Moore Via E-Mail Re: Separation and Consulting Agreement Dear Tim: This letter sets forth the terms of the separation and consulting agreement (the “Agreement”) that Instil Bio, Inc. (the “Company”) is offering to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employme |
|
| March 31, 2023 |
Non-Employee Director Compensation Policy instilbio-nonxemployeedi 1 INSTIL BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Instil Bio, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or |
|
| March 31, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 INSTIL BIO, INC. LIST OF SUBSIDIARIES Name of Entity Jurisdiction of Organization 1. Instil Bio (UK) Limited United Kingdom 2. Cellular Therapeutics Limited United Kingdom 3. Complex Therapeutics Mezzanine LLC Delaware 4. Complex Therapeutics LLC Delaware |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 27, 2023 |
Form of Retention Bonus Agreement. February 22, 2023 [NAME] Re: One-Year Retention Bonus Agreement for Executive Officers Dear [NAME]: As you have been informed, Instil Bio, Inc. |
|
| February 14, 2023 |
TIL / Instal Bio / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INSTIL BIO, INC. (Name of Issuer) Common Stock, $0.000001 par value per share (Title of Class of Securities) 45783C101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 1, 2023 |
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U. |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 9, 2023 |
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer –Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause –Initial data readout for ITIL-306 expected in 2023 –With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding potential financing or other monetization of Tarzana manufacturing site DALLAS, TX, January 9, 2023 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| December 8, 2022 |
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce –Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 –Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma –Reducing U. |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2022 |
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1?23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. |
|
| November 14, 2022 |
1. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) by and between Timothy Moore (?Employee?) and Instil Bio Inc. (the ?Company?) is effective as of September 6, 2022 (the ?Effective Date?). The Company desires to employ Employee as its Chief Operating Officer (COO) and, in connection therewith, to compensate Employee for Employee?s personal services to the Company; and Employee wi |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 8, 2022 |
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting DALLAS, TX, November 8, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 18, 2022 |
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FR?), in Non-Small Cell Lung Cancer ?ITIL-306 is a novel TIL therapy engineered with our CoStAR platform (CoStAR-TIL) targeting folate receptor alpha which is designed to boost TIL activity in the tumor microenvironment ?CoStAR-T cells demonstrate enha |
|
| September 6, 2022 |
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer DALLAS, TX, September 6, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 12, 2022 |
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material 28722485. |
|
| August 12, 2022 |
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H 2023 with top-line clinical data expected in early 2024 Phase 1 study initiated for ITIL-306, Instil?s first CoStAR-TIL product candidate Phase 1 study initiated for ITIL-168 in combination with pembrolizumab (DELTA-2) for NSCLC, cervical cancer, and squamous cell carcinoma of the head and neck DALLAS, TX, August 12, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exac |
|
| August 12, 2022 |
29949910.v4 MEZZANINE LOAN AGREEMENT Dated as of June 10, 2022 Between COMPLEX THERAPEUTICS MEZZANINE LLC, as Borrower and OPG HERMES INVESTMENTS (DE) LLC, as Lender Property: 18408-18412 Oxnard Street, Los Angeles, California Loan Amount: $30,000,000 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Regi |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 22, 2022 |
TIL / Instal Bio / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INSTIL BIO, INC. (Name of Issuer) Common Stock, $0.000001 par value per share (Title of Class of Securities) 45783C101 (CUSIP Number) June 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 27, 2022 |
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed To Enhance Activity in the Tumor Microenvironment ?FDA granted IND clearance for ITIL-306, Instil?s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer ?Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and tumor control at the 2022 ASCO Annual Meeting ?ITIL-306 Phase 1 clinical study will enroll first patient with NSCLC and feature a regimen free of post-infusion IL-2 DALLAS, TX, May 27, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| May 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 18, 2022 |
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) Presentation to highlight correlates of response to TIL product attributes and elements of Instil Bio?s cell therapy data analytics and computational platform DALLAS, TX, May 18, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| May 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 16, 2022 |
DocuSign Envelope ID: 21A55229-52A4-4DD4-8E7B-6355675C11F9 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) by and between Vijay Chiruvolu (?Executive?) and Instil Bio Inc. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exa |
|
| May 16, 2022 |
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update ?Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022 ?Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022 ?Cash runway into 2024 through key clinical data expected in 2023 DALLAS, TX, May 16, 2022 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| April 1, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between INSTIL BIO, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of [?] a |
|
| April 1, 2022 |
As filed with the Securities and Exchange Commission on April 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 1, 2022 Registration No. |
|
| April 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Instil Bio, Inc. |
|
| April 1, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.9 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between INSTIL BIO, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws |
|
| April 1, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 INSTIL BIO, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF INSTIL BIO, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between INSTIL BIO, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws |
|
| April 1, 2022 |
Exhibit 4.4 INSTIL BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 7 Section 2. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini |
|
| March 30, 2022 |
DEF 14A 1 instilbioproxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission |
|
| March 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2022 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exact na |
|
| March 7, 2022 |
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U. |
|
| March 7, 2022 |
DESCRIPTION OF COMMON STOCK The following description summarizes the most important terms of our common stock. |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 15, 2021 |
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting DALLAS, TX, November 15, 2021 (GLOBE NEWSWIRE) ? Instil Bio, Inc. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 15, 2021 |
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update ?Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1) ?Fast Track Designation granted by FDA for ITIL-168 in metastatic melanoma ?CoStAR mechanism of action data presented at SITC 2021 ?Successful pre-IND meeting for ITIL-306 DALLAS, TX, November 15, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| September 16, 2021 |
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress DALLAS, TX, September 16th, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| September 13, 2021 |
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma Additional Cohorts: ITIL-168 clinical trial expanded during IND review process with two additional cohorts, broadening the study target population DALLAS, TX, September 13, 2021 (GLOBE NEWSWIRE) - Instil Bio, Inc. |
|
| September 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exac |
|
| August 12, 2021 |
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from the U. |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40215 Instil Bio, Inc. (Exa |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 13, 2021 |
EX-99.1 2 q1-21earningspressrelease.htm EX-99.1 Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update IPO in March 2021 raising $368M in gross proceeds Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168 DALLAS, TX, May 13, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company d |
|
| April 27, 2021 |
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma DALLAS, TX, April 27, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| April 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 20, 2021 |
As filed with the Securities and Exchange Commission on April 20, 2021 Registration No. |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Instil Bio, Inc. (Name of Issuer) Common Stock, $0.000001 par value (Title of Class of Securities) 45783C101 (CUSIP Number) March 23, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| April 13, 2021 |
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting 67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, TX, April 12, 2021 (GLOBE NEWSWIRE) Instil Bio, Inc. |
|
| April 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 5, 2021 |
SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 (Title of Class of Securities) 4578C101 (CUSIP NUMBER) Curative Ventures V LLC 3963 Maple Avenue Suite 390 Dallas, Texas 75219 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| April 5, 2021 |
Exhibit A Joint Filing Agreement The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Instil Bio, Inc. |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Instil Bio, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 45783C101 (CUSIP Number) John Bateman CPMG, Inc. 2000 McKinney Ave, Suite 2125 Dallas, Texas 75201 214-871-6816 (Name, Address and Telephone Numbe |
|
| April 1, 2021 |
EX-99.A 2 brhc10022588ex99-a.htm EXHIBIT A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Instil Bio, Inc., dated as of April 1, 2021, is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Instil Bio, Inc. (Name of Issuer) Common stock, par value $ 0.000001 per share (Title of Class of Securities) 45783C101 (CUSIP Number) March 23, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Instil Bio, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-40215 83-2072195 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 23, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INSTIL BIO, INC. (A DELAWARE CORPORATION) March 23, 2021 INSTIL BIO, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., 3500 S. Dupont Hwy, in the city of Dover, county of Kent, Delaware 19901, and said corporation, or oth |
|
| March 23, 2021 |
Exhibit 3.1 INSTIL BIO, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Instil Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: FIRST: That the name of this corporation is Instil Bio, Inc. The original Certificate of Incorporation of the Company was filed with the Delaware Secretary of State on August 31 |
|
| March 22, 2021 |
16,000,000 Shares Instil Bio, Inc. COMMON STOCK Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-253620 16,000,000 Shares Instil Bio, Inc. COMMON STOCK Instil Bio, Inc. is offering 16,000,000 shares of common stock. This is our initial public offering and no public market exists for our common stock. The initial public offering price is $20.00 per share. Our common stock has been approved for listing on The Nasdaq Global |
|
| March 18, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 18, 2021. |
|
| March 16, 2021 |
March 16, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell and Celeste Murphy Re: Instil Bio, Inc. Registration Statement on Form S-1 File No. 333-253620 Acceleration Request Requested Date: March 18, 2021 Requested Time: 4:00 p.m., Eastern Standard Time Ladies and Gentlemen: In accordance with Rule 461 under |
|
| March 16, 2021 |
Instil Bio, INC. 3963 Maple Avenue, Suite 350 Dallas, TX 75219 March 16, 2021 Via Edgar Instil Bio, INC. 3963 Maple Avenue, Suite 350 Dallas, TX 75219 March 16, 2021 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Julie Sherman Vanessa Robertson Alan Campbell Celeste Murphy RE: Instil Bio, Inc. Registration Statement on Form S-1 File No. 333-253620 Acceleration Request Requested Date: March 18, |
|
| March 15, 2021 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com CORRESP 1 filename1.htm Divakar Gupta +1 212 479 6474 [email protected] March 15, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Julie Sherman Vanessa Robertson Alan Campbell Celeste Murphy Re: Instil Bio, Inc. Registration Statement on Form S-1 Filed February 26, 2021 File No. 333-253620 Ladies and Gentlemen: On behalf of |
|
| March 15, 2021 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSTIL BIO, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the state of Delaware) Instil Bio, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the state of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o |
|
| March 15, 2021 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) by and between Zachary Roberts (?Executive?) and Instil Bio Inc. (the ?Company?) is effective as of the date of the closing of the first sale of the Company?s Series B Preferred Stock (the ?Effective Date?) and amends and restates in its entirety the Offer Le |
|
| March 15, 2021 |
Exhibit 10.2 INSTIL BIO, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 2021 APPROVED BY THE STOCKHOLDERS: MARCH 2021 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 7 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; O |
|
| March 15, 2021 |
Form of Indemnification Agreement with Executive Officers and Directors Exhibit 10.5 INSTIL BIO, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of , 20 , and is between Instil Bio, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. Indemnitee?s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain ot |
|
| March 15, 2021 |
8-A12B 1 d140583d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Instil Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 83-2072195 (State of incorporation or organization) (I.R.S. Employer Identificatio |
|
| March 15, 2021 |
2021 Employee Stock Purchase Plan Exhibit 10.4 INSTIL BIO, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 2021 APPROVED BY THE STOCKHOLDERS: MARCH 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series |
|
| March 15, 2021 |
Bylaws of the Registrant (currently in effect) Exhibit 3.3 BYLAWS OF INSTIL BIO, INC. TABLE OF CONTENTS Page Article I Corporate Offices 1 1.1 Principal Office 1 1.2 Other Offices 1 Article II Meetings of Stockholders 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 2 2.5 Manner of Giving Notice; Affidavit of Notice 2 2.6 Quorum 2 2.7 Adjourned Meeting; Notice 2 2.8 Organization; Conduct |
|
| March 15, 2021 |
Exhibit 3.5 INSTIL BIO, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., 3500 S. Dupont Hwy, in the city of Dover, county of Kent, Delaware 19901, and said corporation, or other such person or entity as the Board of Directors may from time to time designate, shal |
|
| March 15, 2021 |
Exhibit 10.8 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) by and between Sandeep Laumas (?Executive?) and Instil Bio Inc. (the ?Company?) is effective as of the date of the closing of the first sale of the Company?s Series B Preferred Stock (the ?Effective Date?) and amends and restates in its entirety the Offer Let |
|
| March 15, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [?] Shares INSTIL BIO, INC. COMMON STOCK, PAR VALUE $0.000001 PER SHARE UNDERWRITING AGREEMENT [?], 2021 [?], 2021 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lex |
|
| March 15, 2021 |
Exhibit 3.4 INSTIL BIO, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Instil Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: FIRST: That the name of this corporation is Instil Bio, Inc. The original Certificate of Incorporation of the Company was filed with the Delaware Secretary of State on August 31 |
|
| March 15, 2021 |
Exhibit 10.6 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) by and between Bronson Crouch (?Executive?) and Instil Bio Inc. (the ?Company?) is effective as of the date of the closing of the first sale of the Company?s Series B Preferred Stock (the ?Effective Date?) and amends and restates in its entirety the Employmen |
|
| March 15, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 15, 2021. |
|
| March 15, 2021 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSTIL BIO, INC. Instil Bio, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), hereby certifies that: 1. The name of this corporation is Instil Bio, Inc. (the ?Corporation?), and that this Corporatio |
|
| March 8, 2021 |
CORRESP 1 filename1.htm Divakar Gupta +1 212 479 6474 [email protected] *FOIA Confidential Treatment Request* Confidential Treatment Requested by Instil Bio, Inc. in connection with Registration Statement on Form S-1 (File No. 333-253620) March 8, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Julie Sherma |
|
| February 26, 2021 |
Share Purchase Agreement, by and between the Registrant and Immetacyte Limited, dated March 2, 2020 Exhibit 10.1 Certain information has been excluded from this agreement (indicated by ?[***]?) because Instil Bio, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION AGREEMENT FOR THE SALE AND PURCHASE OF THE ENTIRE ISSUED SHARE CAPITAL OF IMMETACYTE LIMITED (1) SELLERS (2) INSTIL BIO INC. (3) SELLERS? REPRESENTA |
|
| February 26, 2021 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSTIL BIO, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the state of Delaware) Instil Bio, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the state of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o |
|
| February 26, 2021 |
Exhibit 10.3 INSTIL BIO, INC. 2018 STOCK INCENTIVE PLAN Adopted by the Board on September 20, 2018 Approved by the Stockholders on October 3, 2018 TABLE OF CONTENTS Page SECTION 1. PURPOSE 1 SECTION 2. DEFINITIONS 1 2.1 ?Affiliate? 1 2.2 ?Award? 1 2.3 ?Award Agreement? 1 2.4 ?Board? 1 2.5 ?Cause? 1 2.6 ?Change in Control? 2 2.7 ?Code? 3 2.8 ?Committee? 3 2.9 ?Company? 3 2.10 ?Consultant? 3 2.11 ?D |
|
| February 26, 2021 |
Bylaws of the Registrant (currently in effect) Exhibit 3.2 BYLAWS OF INSTIL BIO, INC. TABLE OF CONTENTS Page Article I Corporate Offices 1 1.1 Principal Office 1 1.2 Other Offices 1 Article II Meetings of Stockholders 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 2 2.5 Manner of Giving Notice; Affidavit of Notice 2 2.6 Quorum 2 2.7 Adjourned Meeting; Notice 2 2.8 Organization; Conduct |
|
| February 26, 2021 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com Divakar Gupta +1 212 479 6474 [email protected] February 26, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Julie Sherman Vanessa Robertson Alan Campbell Celeste Murphy Re: Instil Bio, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted February 12, 2021 CIK No. 0001789769 Ladies and Gentlemen: On be |
|
| February 26, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on February 26, 2021. |
|
| February 26, 2021 |
Exhibit 4.1 INSTIL BIO, INC. SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of December 30, 2020, by and among Instil Bio, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto (together with any subsequent investors, or transferees who become parties h |
|
| February 12, 2021 |
INSTIL BIO, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 INSTIL BIO, INC. SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of December 30, 2020, by and among Instil Bio, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto (together with any subsequent investors, or transferees who become parties h |
|
| February 12, 2021 |
Exhibit 10.3 INSTIL BIO, INC. 2018 STOCK INCENTIVE PLAN Adopted by the Board on September 20, 2018 Approved by the Stockholders on October 3, 2018 TABLE OF CONTENTS Page SECTION 1. PURPOSE 1 SECTION 2. DEFINITIONS 1 2.1 ?Affiliate? 1 2.2 ?Award? 1 2.3 ?Award Agreement? 1 2.4 ?Board? 1 2.5 ?Cause? 1 2.6 ?Change in Control? 2 2.7 ?Code? 3 2.8 ?Committee? 3 2.9 ?Company? 3 2.10 ?Consultant? 3 2.11 ?D |
|
| February 12, 2021 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on February 12, 2021. |
|
| February 12, 2021 |
Cooley LLP 55 Hudson Yards New York, NY 10001-2157 t: (212) 479-6000 f: (212) 479-6275 cooley.com Divakar Gupta +1 212 479 6474 [email protected] February 12, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Julie Sherman Vanessa Robertson Alan Campbell Celeste Murphy Re: Instil Bio, Inc. Draft Registration Statement on Form S-1 Submitted January 12, 2021 CIK No. 0001789769 Ladies and Gentlemen: On behalf of Instil Bio, |
|
| February 12, 2021 |
Exhibit 3.2 BYLAWS OF INSTIL BIO, INC. TABLE OF CONTENTS Page Article I Corporate Offices 1 1.1 Principal Office 1 1.2 Other Offices 1 Article II Meetings of Stockholders 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Stockholders? Meetings 2 2.5 Manner of Giving Notice; Affidavit of Notice 2 2.6 Quorum 2 2.7 Adjourned Meeting; Notice 2 2.8 Organization; Conduct |
|
| February 12, 2021 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INSTIL BIO, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the state of Delaware) Instil Bio, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the state of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o |
|
| January 12, 2021 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on January 12, 2021. |
